Loading...
AbCellera Q1 2025 Earnings Report
AbCellera reported its Q1 2025 business results, with total revenue of $4.2 million and a net loss of $45.6 million.
Key Takeaways
AbCellera reported a total revenue of $4.2 million for Q1 2025, a decrease from $10.0 million in Q1 2024. The company experienced a net loss of $45.6 million, compared to a net loss of $40.6 million in the prior year. Despite the loss, AbCellera maintained strong liquidity with over $800 million in available funds and is advancing new antibody programs into clinical trials.
Total revenue for Q1 2025 was $4.2 million, primarily from research fees.
Net loss for Q1 2025 was $45.6 million, or $(0.15) per share.
The company ended the quarter with over $800 million in available liquidity.
AbCellera plans to start Phase 1 clinical trials for ABCL635 and ABCL575 in the second half of 2025.
AbCellera
AbCellera
AbCellera Revenue by Segment
Revenue by Segment
Research Fees Revenue
CapyFin.comLicensing Revenue
CapyFin.com Forward Guidance
AbCellera anticipates starting Phase 1 clinical trials for ABCL635 and ABCL575 in the second half of 2025, leveraging its strong liquidity to execute its strategy.
Positive Outlook
- Introduction of ABCL635 as a potential first-in-class antibody for vasomotor symptoms.
- ABCL635 is positioned as a next-generation NK3R antagonist with improved safety and convenient dosing.
- Potential for ABCL635 to be a highly differentiated product in a large market.
- Anticipated start of Phase 1 clinical trials for ABCL635 and ABCL575 in H2 2025.
- Strong available liquidity of over $800 million to execute strategy.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- The report does not specify any anticipated challenges or risks for the upcoming periods.
- No explicit warnings about potential revenue declines or increased losses were given.
- No mention of potential delays in clinical trials.
- No information on potential changes in market conditions that could negatively impact future results.